Rendering

Component: (Network and Table)
Network
080500 - Disclosure - CREDIT AGREEMENT (Tables)
(http://pharmerica.com/role/CreditAgreementTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001388195 (http://www.sec.gov/CIK)
CREDIT AGREEMENT [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
CREDIT AGREEMENT [Abstract]
 
Schedule of Term Debt and Revolving Credit Facility
PHARMERICA CORPORATION
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

NOTE 5—CREDIT AGREEMENT (Continued)
 
The table below summarizes the total outstanding debt of the Corporation (dollars in millions):
 
 
 
December 31, 2015
  
December 31, 2016
 
Term Debt - payable to lenders at LIBOR plus applicable margin (2.77% as of December 31, 2016), matures September 17, 2019
 
$
219.4
  
$
297.2
 
Revolving Credit Facility payable to lenders, interest at LIBOR plus applicable margin (2.72% as of December 31, 2016), matures September 17, 2019
  
207.0
   
176.5
 
Deferred financing costs, net
  
(2.1
)
  
(1.9
)
Capital lease obligations
  
0.9
   
1.6
 
Total debt
  
425.2
   
473.4
 
Less: Current portion of long-term debt
  
11.6
   
15.6
 
Total long-term debt
 
$
413.6
  
$
457.8
 


  
Schedule of Indebtedness Maturities
The Corporation's indebtedness has the following maturities (dollars in millions):
 
Year Ending December 31,
 
Term Debt
  
Revolving
Credit
Facility
  
Deferred Financing Costs
  
Capital
Lease
Obligations
  
Total
Maturities
 
2017
 
$
15.0
  
$
-
  
$
(0.7
)
 
$
0.6
  
$
14.9
 
2018
  
15.0
   
-
   
(0.7
)
  
0.4
   
14.7
 
2019
  
267.2
   
176.5
   
(0.5
)
  
0.4
   
443.6
 
2020
  
-
   
-
   
-
   
0.2
   
0.2
 
2021
  
-
   
-
   
-
   
-
   
-
 
 
 
$
297.2
  
$
176.5
  
$
(1.9
)
 
$
1.6
  
$
473.4